Hepatitis B and C Antiviral Therapy

Understanding antiviral therapy for Hepatitis B (HBV) and Hepatitis C (HCV) is a cornerstone of modern hepatology and infectious disease. These treatments have transformed once-chronic, debilitating illnesses into manageable or even curable conditions, dramatically reducing the risk of cirrhosis and liver cancer. While both target viral hepatitis, their mechanisms, goals, and outcomes are fundamentally different, a distinction critical for any future clinician to master.

Nucleoside Analogs: The Foundation of HBV Suppression

Unlike HCV, HBV is a DNA virus that replicates via reverse transcription. The primary goal of HBV therapy is not eradication but long-term suppression of viral replication to prevent liver damage. This is achieved using nucleoside/nucleotide analogs (NAs), which are oral medications that mimic the building blocks of viral DNA.

These drugs work by inhibiting the HBV DNA polymerase, the enzyme responsible for copying the viral genome. When the polymerase incorporates the drug molecule into the growing DNA chain, it causes premature chain termination, halting viral replication. Two first-line agents are central to this strategy. Entecavir is a potent nucleoside analog with a high barrier to resistance, meaning the virus struggles to mutate and evade its effects. Tenofovir, available as tenofovir disoproxil fumarate (TDF) and the newer tenofovir alafenamide (TAF), is a nucleotide analog equally effective at suppression with an excellent long-term safety profile, particularly regarding kidney and bone health with TAF. Treatment is typically indefinite, as stopping can lead to severe viral rebound and hepatitis flare.

The Revolution of HCV Treatment: Direct-Acting Antivirals

HCV therapy has undergone a seismic shift from poorly tolerated interferon-based regimens to highly effective, all-oral, interferon-free regimens. These modern treatments use direct-acting antivirals (DAAs) that target specific non-structural proteins essential for the HCV life cycle. The aim here is not suppression but cure, defined as a sustained virologic response (SVR), which means no detectable virus in the blood 12 weeks after completing therapy. Achieving SVR is effectively a cure, associated with halted disease progression and reduced liver-related mortality.

DAAs are combined into regimens that attack the virus at multiple points. A classic combination is sofosbuvir, a NS5B polymerase inhibitor, with ledipasvir, an NS5A inhibitor. Sofosbuvir, as a nucleotide analog, acts as a chain terminator for the viral RNA, while ledipasvir disrupts the function of the NS5A protein, which is vital for viral replication and assembly. This powerful synergy allows for high cure rates with just 8-12 weeks of treatment for many patients.

Pangenotypic Regimens and Modern DAA Combinations

Early DAAs were genotype-specific, requiring complex testing before treatment. The field has moved toward pangenotypic activity, meaning a single regimen is effective against all major HCV genotypes (1-6). This simplifies treatment algorithms immensely. The leading example is glecaprevir-pibrentasvir, a fixed-dose combination pill. Glecaprevir is an NS3/4A protease inhibitor, which blocks a protein that cleaves the viral polyprotein into active components. Pibrentasvir is an NS5A inhibitor. Together, they offer a highly effective, well-tolerated, pangenotypic option, often used as a first-line therapy for most patients, including those with compensated cirrhosis.

Modern regimens are tailored but generally fall into classes: NS5B polymerase inhibitors (sofosbuvir), NS5A inhibitors (ledipasvir, pibrentasvir, velpatasvir), and NS3/4A protease inhibitors (glecaprevir). Combining drugs from different classes maximizes efficacy and minimizes the risk of resistance.

The Critical Distinction: Cure vs. Suppression

This is the most pivotal conceptual takeaway. For HCV, treatment with DAAs aims for and achieves a virologic cure (SVR). The virus is eliminated, and ongoing therapy is not required. For HBV, current first-line oral agents (entecavir, tenofovir) induce profound suppression, but they rarely eradicate the virus due to its persistence as covalently closed circular DNA (cccDNA) within the nucleus of hepatocytes. Therefore, HBV therapy is usually lifelong. Confusing these two fundamental outcomes can lead to serious errors in patient counseling and management.

Common Pitfalls

1. Stopping HBV Therapy Prematurely: A dangerous mistake is discontinuing entecavir or tenofovir because the patient "feels fine" or viral DNA is undetectable. This can precipitate acute-on-chronic liver failure due to severe viral rebound. Patients must understand HBV treatment is typically lifelong.
2. Misinterpreting Treatment Goals: Telling an HBV patient the goal is to "cure" their infection sets unrealistic expectations and undermines adherence to long-term therapy. Conversely, failing to communicate the high likelihood of cure for an HCV patient misses a powerful motivational tool.
3. Overlooking Drug-Drug Interactions (DDIs): DAAs, particularly protease inhibitors like glecaprevir, are metabolized by and can affect liver enzymes (CYPs), leading to significant DDIs. For example, they can dangerously increase levels of statins or certain heart medications. A thorough medication reconciliation is mandatory before prescribing.
4. Skipping Baseline and On-Treatment Monitoring: For HBV, not checking renal function before starting tenofovir or failing to monitor viral load periodically can miss toxicity or treatment failure. For HCV, not checking for resistance-associated substitutions in rare cases or confirming SVR at 12 weeks post-treatment neglects standard of care.

Summary

• HBV is managed with long-term suppression using oral nucleoside/nucleotide analogs like entecavir and tenofovir, which inhibit the HBV DNA polymerase.
• HCV is now curable with short-course, oral direct-acting antiviral (DAA) combinations that are part of interferon-free regimens. Cure is confirmed by achieving a sustained virologic response (SVR).
• Key DAA mechanisms include NS5B polymerase inhibitors (e.g., sofosbuvir) and NS5A inhibitors (e.g., ledipasvir). Modern pangenotypic combinations like glecaprevir-pibrentasvir simplify treatment by working against all HCV genotypes.
• The fundamental paradigm difference—cure for HCV vs. suppression for HBV—must guide all patient communication and clinical decision-making.
• Vigilance for drug interactions and adherence to monitoring protocols are essential for safe and effective therapy for both viruses.